Non Invasive Prenatal Testing Market To Reach $8.16 Billion By 2030

Non Invasive Prenatal Testing Market Growth & Trends

The global non invasive prenatal testing market size is expected to reach USD 8.16 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 10.06% from 2024 to 2030. Increasing incidence of chromosomal abnormalities is expected to accelerate market growth. Of all the countries, there is a substantial opportunity in China for non invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue. Thus, this high incidence rate is anticipated to boost the demand for prenatal tests.

With lockdowns due to COVID-19, NIPT gained attention because it delivers high accuracy screening with minimum risk of infection compared to invasive procedures like chorionic villus sampling and amniocentesis, both of which may necessitate hospitalization and put patients and medical professionals at risk of contracting COVID-19 infection. Moreover, there was increased demand for prescription of NIPTs; however, it was limited to a smaller number of eligible people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario pertaining to non invasive prenatal testing is highly variable. However, the support from the government and favorable insurance policies boost market growth. For instance, in the Netherlands, prenatal testing expenses are fully reimbursed in the second trimester, leading to increased adoption of these tests. Increase in government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China is anticipated to boost the demand for noninvasive prenatal testing solutions and services.

Key players in the market are focusing on new product development to strengthen their product portfolios and offer innovative products to customers. In March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetic laboratories. The probes on the cyto microarrays offer high-resolution detection of copy number variation and copy-neutral loss of heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.

 Request a free sample copy or view report summary: Non Invasive Prenatal Testing Market Report

Non Invasive Prenatal Testing Market Report Highlights

• By gestation period, 13-24 weeks dominated the market in 2023 owing to the maximum number of non-invasive prenatal procedures carried out in the second trimester of the pregnancy

• The low-risk pregnancy risk segment is expected to witness significant growth over the forecast period. Support from the government such as budget assignment for average-risk pregnancies contributed to the segment growth

• Based on product, the cell-free DNA in maternal plasma tests segment accounted for the largest revenue share in 2023. Cell-free DNA is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses

• Asia Pacific is expected to exhibit the highest CAGR over the forecast period. Rising maternal age and improving healthcare infrastructure are likely to strengthen the market growth

• North America dominated the market in 2023 due to high R&D investments, the presence of advanced healthcare facilities, and the development of whole genome sequencing

Non Invasive Prenatal Testing Market Segmentation

Grand View Research has segmented the global non invasive prenatal testing market report based on gestation period, pregnancy risk, method, technology, product, application, end-use, and region

Non Invasive Prenatal Testing Gestation Period Outlook (Revenue, USD Million, 2018 - 2030)

• 0-12 Weeks

• 13-24 Weeks

• 25-36 Weeks

Non Invasive Prenatal Testing Pregnancy Risk Outlook (Revenue, USD Million, 2018 - 2030)

• High & Average Risk

• Low Risk

Non Invasive Prenatal Testing Method Outlook (Revenue, USD Million, 2018 - 2030)

• Ultrasound Detection

• Biochemical Screening Tests

• Cell-free DNA in Maternal Plasma Tests

Non Invasive Prenatal Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• NGS

• Array Technology

• PCR

• Others

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Consumables & Reagents

• Instruments

Non Invasive Prenatal Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Trisomy

• Microdeletion Syndrome

• Other Applications

Non Invasive Prenatal Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostic Laboratories

Non Invasive Prenatal Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Non Invasive Prenatal Testing Market

• Genesis Genetics (CooperSurgical, Inc.)

• Natera, Inc.

• Eurofins LifeCodexx GmbH

• Illumina, Inc. (Verinata Health, Inc.)

• Centogene N.V.

• MedGenome Labs Ltd.

• Myriad Women’s Health, Inc. (Counsyl, Inc.)

• F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)

• Qiagen

• Laboratory Corp. of America Holdings

• Progenity, Inc.

• Quest Diagnostics, Inc.